381 related articles for article (PubMed ID: 28945937)
1. Resveratrol and inflammatory bowel disease.
Shi Y; Zhou J; Jiang B; Miao M
Ann N Y Acad Sci; 2017 Sep; 1403(1):38-47. PubMed ID: 28945937
[TBL] [Abstract][Full Text] [Related]
2. Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease.
Sreedhar R; Arumugam S; Thandavarayan RA; Karuppagounder V; Watanabe K
Drug Discov Today; 2016 May; 21(5):843-9. PubMed ID: 26995272
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol and resveratrol nano-delivery systems in the treatment of inflammatory bowel disease.
Gowd V; Kanika ; Jori C; Chaudhary AA; Rudayni HA; Rashid S; Khan R
J Nutr Biochem; 2022 Nov; 109():109101. PubMed ID: 35777588
[TBL] [Abstract][Full Text] [Related]
4. [Polyphenols in the treatment of inflammatory bowel diseases].
Chojnacka K; Laskowska J
Postepy Biochem; 2020 Sep; 66(3):256-262. PubMed ID: 33315320
[TBL] [Abstract][Full Text] [Related]
5. Anti-Inflammatory Effects of Resveratrol in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study.
Samsami-Kor M; Daryani NE; Asl PR; Hekmatdoost A
Arch Med Res; 2015 May; 46(4):280-5. PubMed ID: 26002728
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol and inflammatory bowel disease: the evidence so far.
Nunes S; Danesi F; Del Rio D; Silva P
Nutr Res Rev; 2018 Jun; 31(1):85-97. PubMed ID: 29191255
[TBL] [Abstract][Full Text] [Related]
7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
8. Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease.
Biasi F; Astegiano M; Maina M; Leonarduzzi G; Poli G
Curr Med Chem; 2011; 18(31):4851-65. PubMed ID: 21919842
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory pathways of importance for management of inflammatory bowel disease.
Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
[TBL] [Abstract][Full Text] [Related]
10. Alternative medicines as emerging therapies for inflammatory bowel diseases.
Singh UP; Singh NP; Busbee B; Guan H; Singh B; Price RL; Taub DD; Mishra MK; Nagarkatti M; Nagarkatti PS
Int Rev Immunol; 2012 Feb; 31(1):66-84. PubMed ID: 22251008
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Impact of Cyanidin-3-Glucoside on Inflammatory Bowel Diseases: Investigating New Mechanisms for Emerging Interventions.
Frountzas M; Karanikki E; Toutouza O; Sotirakis D; Schizas D; Theofilis P; Tousoulis D; Toutouzas KG
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298350
[TBL] [Abstract][Full Text] [Related]
12. Conventional drug therapy for inflammatory bowel disease.
Bryant RV; Brain O; Travis SP
Scand J Gastroenterol; 2015 Jan; 50(1):90-112. PubMed ID: 25523560
[TBL] [Abstract][Full Text] [Related]
13. The implications of oxidative stress and antioxidant therapies in Inflammatory Bowel Disease: Clinical aspects and animal models.
Balmus IM; Ciobica A; Trifan A; Stanciu C
Saudi J Gastroenterol; 2016; 22(1):3-17. PubMed ID: 26831601
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?
O'Sullivan M
Proc Nutr Soc; 2015 Feb; 74(1):5-12. PubMed ID: 25490986
[TBL] [Abstract][Full Text] [Related]
15. Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association.
Principi M; Cassano N; Contaldo A; Iannone A; Losurdo G; Barone M; Mastrolonardo M; Vena GA; Ierardi E; Di Leo A
World J Gastroenterol; 2016 May; 22(20):4802-11. PubMed ID: 27239107
[TBL] [Abstract][Full Text] [Related]
16.
Hou M; Leng Y; Shi Y; Tan Z; Min X
Am J Chin Med; 2023; 51(6):1501-1526. PubMed ID: 37530507
[TBL] [Abstract][Full Text] [Related]
17. [Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH].
Dejaco C; Haas T; Kirchgatterer A; Miehsler W; Wenzl H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W; Tilg H
Z Gastroenterol; 2006 Jun; 44(6):525-38; discussion 539. PubMed ID: 16773519
[TBL] [Abstract][Full Text] [Related]
18. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
19. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.
Ahluwalia B; Moraes L; Magnusson MK; Öhman L
Scand J Gastroenterol; 2018 Apr; 53(4):379-389. PubMed ID: 29523023
[TBL] [Abstract][Full Text] [Related]
20. Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.
Zatorski H; Sałaga M; Fichna J
Naunyn Schmiedebergs Arch Pharmacol; 2019 Nov; 392(11):1321-1330. PubMed ID: 31359088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
